Keryx Biopharmaceuticals Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KERX Revenue Growth Range, Past 5 Years
| Minimum | -79.35% | Sep 2005 |
| Maximum | 96.03% | Jun 2006 |
| Average | 7.53% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these KERX related companies
KERX News
Keryx to Present at 14th Annual BIO CEO & Investor Conference; $KERX http://stks.co/2LF8
about 3 days ago by keryxbiopharma
about 3 days ago by keryxbiopharma
Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference
Feb 08, 8:30AM PR Newswire
Feb 08, 8:30AM PR Newswire
January's bullish run continues this month for $KERX 3.63+0.12, lots of upside with analysts' average consensus price target of 10.29
about 9 days ago by silverjet2
about 9 days ago by silverjet2
Congrats to those who sold in morning, sorry if you remain bag holder $KERX very weak now $$
about 11 days ago by peterumble
about 11 days ago by peterumble
@peterumble Good call on $kerx selling off! Foolish to buy on this dip?
about 11 days ago by ChasinCheddar
about 11 days ago by ChasinCheddar
My brother told me about $kerx last week, didn't jump in. Wish i had, congrats longs!
about 11 days ago by ChasinCheddar
about 11 days ago by ChasinCheddar
$kerx was a steal down here. i added to my macros. have a 14 buck price tgt on it gang
about 11 days ago by Proptr4d3r
about 11 days ago by Proptr4d3r
Inovio Pharmaceuticals and Keryx Biopharmaceuticals Benefit From Strengthening Biotech Sector
Jan 25, 8:20AM Marketwire
Jan 25, 8:20AM Marketwire
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Jan 04, 8:30AM PR Newswire
Jan 04, 8:30AM PR Newswire
A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
Dec 14, 9:00AM Marketwire
Dec 14, 9:00AM Marketwire
Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients
Dec 13, 8:28AM Street Insider
Dec 13, 8:28AM Street Insider
Keryx Biopharmaceuticals announces presentation of study for perifosine
Dec 13, 8:21AM theflyonthewall.com
Dec 13, 8:21AM theflyonthewall.com
Oppenheimer Maintains Outperform Rating and $8 PT on KERYX Biopharmaceuticals
Nov 15, 8:30AM Benzinga
Nov 15, 8:30AM Benzinga
Europe Situation Forecasts Change -- Report Highlights NetApp Inc. and Keryx Biopharmaceuticals
Nov 11, 9:00AM Marketwire
Nov 11, 9:00AM Marketwire
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 11, 8:30AM PR Newswire
Nov 11, 8:30AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 3.20 | -0.10 | -3.03% | 223.04M |
| HTCO | 11.74 | -0.26 | -2.17% | 157.08M |
| GAIA | 3.64 | 0.15 | 4.30% | 84.88M |
| ANEN | 18.30 | -0.15 | -0.81% | 275.23M |
| BEST | 0.62 | -0.11 | -15.07% | 17.07M |
| AAPL | 493.42 | 0.25 | 0.05% | 458.59B |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| MLNX | 36.66 | -0.12 | -0.33% | 1.44B |
| ACHN | 9.89 | 0.42 | 4.49% | 689.88M |
| VECO | 28.36 | 0.08 | 0.28% | 1.10B |
